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Abstract: Fixed-dose combination topical ther-
apy with corticosteroid and vitamin D analog
provides effective treatment and possible
long-term management of psoriasis. The
anti-inflammatory and immunomodulatory
effects of corticosteroids and vitamin D analogs
in treating psoriasis are well investigated; their
complementary effects lead to the disruption of
the inflammatory feedback loop underlying
psoriasis pathogenesis. Recent preclinical data
showed that combination therapy is more
effective than monotherapies of the active
ingredients in preventing activation of resting
pro-inflammatory cells, inducing
immunomodulation, reducing inflammatory
responses by regulating T cell production, and
normalizing keratinocytes. The increased
understanding of the mechanism of action of
fixed-dose combination therapy from preclini-
cal studies is supported by several clinical
studies. As the efficacy of topical therapy is
correlated with the skin penetration of the
active ingredients, new drug delivery systems
have been developed. The fixed-dose combina-
tion Cal/BD aerosol foam creates a modified
supersaturated formulation when applied to the
skin, which is maintained for at least 26 h in the
laboratory setting. Clinical studies have
demonstrated superior efficacy of fixed-dose
combination calcipotriol (Cal) 50 lg/g and
betamethasone dipropionate (BD) 0.5 mg/g
aerosol foam compared with monotherapies of
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the active ingredients. Furthermore, Cal/BD
aerosol foam has shown significantly improved
efficacy compared with more traditional for-
mulations, such as Cal/BD ointment and gel, in
other studies. Calcipotriol also mitigates risks
associated with betamethasone dipropionate
and vice versa, resulting in the favorable safety
profile observed with fixed-dose combination
treatment. Recent data also suggest that fix-
ed-dose combination treatment could provide
long-term management of psoriasis, although
further clinical investigations are needed.
Overall, these data support the value of fix-
ed-dose combination therapy of corticosteroid
and vitamin D analog and highlight the added
potential of innovative drug delivery for the
treatment of psoriasis.
Funding: LEO Pharma.
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INTRODUCTION
Plaque psoriasis is a chronic, inflammatory,
immune-mediated skin disorder characterized
by recurrent itchy, scaly, erythematous plaques
[1]. The burden of psoriasis on a patient’s
quality of life (QoL) may be considerable; this
burden is not only physical (e.g., painful and
debilitating effects of plaques), but also psy-
chologic, with effects including depression,
alexithymia, coping with feelings of stigmati-
zation, and suicide ideation [2].
Topical treatments containing corticos-
teroids and vitamin D analogs, used separately,
together, or in a fixed combination, are essen-
tial and well-established first-line treatments for
patients with mild-to-moderate psoriasis [3, 4].
Although patients with moderate-to-severe
psoriasis are commonly treated with pho-
totherapy and systemic therapies, including
biologic agents [5, 6], the combination of these
therapies with topical treatments can help to
individually optimize disease control and
long-term management [7].
The increased understanding of psoriasis
pathogenesis has provided further insights into
therapeutic targets, and new treatments for
psoriasis are becoming available [5, 6, 8]. That
being said, critical issues related to topical
therapies are still unresolved, including the
poor treatment adherence due to perceived lack
of efficacy and the cumbersome nature of
available treatments [9, 10]. Although there are
no new compounds available, considerable
research has been undertaken for topical treat-
ments to: (1) improve efficacy by enhancing the
drug delivery and bioavailability of active
ingredients, without compromising safety
[11, 12], (2) enhance the convenience of appli-
cation, and (3) increase the variety of available
formulations [11]. New topical formulations
with greater efficacy and more convenient
application could lead to better adherence and
provide subsequent long-term maintenance of a
disease-free state.
This review will examine the anti-inflam-
matory and immunomodulatory mechanisms
of action of fixed-dose combination corticos-
teroid and vitamin D analog versus monother-
apies of the active ingredients, the drug delivery
challenges, and the clinical relevance of these
data. The article presented here is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
THE CURRENT UNDERSTANDING
OF PSORIASIS PATHOGENESIS
In individuals with a genetic predisposition,
environmental factors, such as physical and
psychologic stress, may trigger the initiation of
psoriasis, beginning with the activation of
dendritic cells. The key steps in psoriasis
pathogenesis are summarized in Fig. 1, with
further descriptions below [1, 13].
1. Dendritic cell cytokine release The skin inflam-
matory response is elicited by activated
inflammatory dendritic cells, which secrete
pro-inflammatory cytokines, such as inter-
leukin (IL)-23, IL-12, and tumor necrosis
factor (TNF)-a [1, 13, 14].
2. Activation of the adaptive immune response
Cytokines produced by dendritic cells also
promote the differentiation and activation
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of naı¨ve, or resting, T-cells to effector,
helper (Th1/17), and cytotoxic (Tc1/17)
T-cells. Evidence also suggests that the
altered balance between helper T-cells
(Th1 and Th2) contributes to psoriasis
pathogenesis by further promoting autoim-
mune reactions [1, 15–18].
3. Type 1 T-cell cytokine release The activated
Th1 and Tc1 cells within the skin release
TNF-a and interferon (IFN)-c, which further
support the activation and maturation of
dendritic cells and also promote ker-
atinocyte activation [1, 13, 15, 16, 19].
4. Type 17 T-cell cytokine release Similarly,
activated Th17 and Tc17 cells within the
skin release IL-17 and IL-22, which promote
keratinocyte activation [13, 15, 16, 19, 20].
5. Keratinocyte activation The activation of ker-
atinocytes promotes their hyperproliferation
and atypical differentiation, causing psoriatic
plaque formation on the skin [16, 21–23].
6. Activation of the innate immune response
Innate immune cells, such as neutrophils,
may respond quickly to IL-17 [21].
7. Keratinocyte pro-inflammatory mediator release
This in turn leads to the production of
additional inflammatory mediators, includ-
ing IL-6, IL-8, IL-17C, IL-20, TNF-a, IFN-c,
and antimicrobial peptides (AMPs), which
recruit and activate cells of the innate and
adaptive immune system [16, 21, 24–26].
Interactions between the keratinocytes and
extracellular matrix (ECM) also promote
tissue reorganization and the deposition of
the ECM [1, 13, 17, 26, 27].
A pro-inflammatory feedback loop is then
established among keratinocytes, immune cells,
and components of the extracellular matrix
(e.g., collagen), leading to sustained, active skin
inflammation and subsequent reorganization of
the ECM [1, 15, 16].
Fig. 1 Key components in the pathogenesis of psoriasis. AMPs antimicrobial peptides, DC dendritic cell, IL interleukin,
IFN interferon, Tc cytotoxic T-cell, Th T-helper cell, TNF tumor necrosis factor
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CORTICOSTEROID AND VITAMIN D
ANALOG COMBINATION THERAPY
RESULTS IN INCREASED
EFFECTIVENESS VERSUS
MONOTHERAPY
IN THE TREATMENT OF PSORIASIS
Corticosteroids and vitamin D analogs comple-
ment one another in treating the key patho-
genic factors of plaque psoriasis [16, 28–30].
Corticosteroids have been used for more than
50 years for the treatment of psoriasis [31, 32],
and their immunosuppressive effects are critical
for inhibiting the pro-inflammatory environ-
ment and T-cell activation [15]. Vitamin D
analogs exert normalizing effects on the
hyperproliferation and abnormal differentia-
tion of keratinocytes and also have
immunomodulatory effects [15, 28].
The treatment goal is to clear the psoriatic
plaques by inhibiting the underlying inflam-
mation and normalizing skin homeostasis, ker-
atinocyte proliferation, and differentiation and
to provide immunomodulation. Combination
therapy, unlike monotherapies, has been shown
to address all these treatment goals as supported
by preclinical data and is further discussed
below.
• Dendritic cell cytokine release Corticosteroids
and vitamin D analogs both inhibit the
release of cytokines, such as IL-23, which
are known to stimulate the innate and
adaptive immune systems. Furthermore,
studies with combination treatment in
in vitro cultured dendritic cells have shown
additive effects, leading to greater inhibition
compared with monotherapies of the active
ingredients (Fig. 2, adapted from Lovato
et al. [27]).
• Th1-cell cytokine release Combination treat-
ment inhibits TNF-a secretion from cyto-
toxic Th1-cells, preventing further activation
and maturation of dendritic cells and acti-
vation of keratinocytes (Fig. 3, adapted from
Bailey et al. [33]) [17, 27].
• Th17-cell cytokine release Data have shown
that pro-inflammatory cytokines (e.g.,
IL-17A) were inhibited significantly more
with combination treatment than
monotherapies of the active ingredients in
cultured and activated cytotoxic and helper
T-cells (Figs. 2, 3) [17, 27]. Reduction of these
pro-inflammatory cytokines can inhibit ker-
atinocyte hyperproliferation and abnormal
differentiation.
• Th2-cell cytokine release Although corticos-
teroids, such as betamethasone dipropi-
onate, suppress IL-10 secretion, vitamin D
analogs, such as calcipotriol, induce Th2-cell
production (Fig. 2) [27].
• Keratinocyte pro-inflammatory mediator release
Keratinocytes in psoriatic plaques release
inflammatory mediators, such as IL-6, IL-8,
IL-17C, IL-20, IFN-c, and AMPs, which leads
to the initiation of the pro-inflammatory
feedback loop. Combination of corticos-
teroids and vitamin D analogs inhibits all
of the aforementioned pro-inflammatory
cytokines more than monotherapies of the
active ingredients (Fig. 2) [27].
In summary, corticosteroid and vitamin D
analog combination therapy inhibits the effects
of Th1 and Th17 cytokines in an additive way
Fig. 2 Combination treatment in vitro is significantly
more effective than monotherapies of the active ingredi-
ents in inhibiting cytokine released from key cells involved
in psoriasis pathogenesis [27]. Pro-inflammatory (IL-23,
IL-17A, and IL-8) and immunomodulatory (IL-10)
cytokine levels released by dendritic cells, T-cells, and
keratinocytes are expressed as percentage of vehicle-treated
control (100%). Treatment was applied before DC
activation, after (IL-17A) and before (IL-10) Th-cell
(CD4?) differentiation, and on stimulated keratinocytes.
DC cultures were differentiated from CD14? cells. CD4?
cells were differentiated into Th1 and Th17 cells and were
processed for ribonucleic acid extraction and quantitative
real-time polymerase chain reaction. KC cells were
obtained from primary human epidermal KCs. *Combi-
nation treatment also led to TNF-a inhibition (both
P\0.001). Similar results were found for the inhibition
of IL-22, IL-8, and TNF-a (all P\0.001). Similar results
were observed for IL-6, IL-17C, and IL-20 (all P\0.001).
BD betamethasone dipropionate, Cal calcipotriol, DC
dendritic cells, IL interleukin, KCs keratinocytes, ns not
significant Adapted from Lovato et al. [27]
c
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(Fig. 3). Corticosteroids can also suppress
immunomodulatory Th2-cells and IL-10 secre-
tion when used alone [17, 18, 27]; additionally,
altering the Th1/Th2 balance has been sug-
gested to further promote autoimmune reac-
tions [17, 18]. The vitamin D analog calcipotriol
complements the effects of corticosteroids by
inducing Th2- and T-reg cell production (Fig. 3)
[17, 27]. Equilibrating the Th1 and Th2 ratio
could therefore provide immunomodulation
and may prevent rebound [18], while T-reg cells
are central to actively attenuating inflammatory
responses via inhibition of effector T-cells
(Fig. 3) [1]. The effect of combination therapy
on cellular targets in the pathophysiology of
psoriasis is summarized in Fig. 4a–d.
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Corticosteroid and Vitamin D Analog
Combination Topical Treatment May Be
Able to Provide Long-Term Management
of Psoriasis
Upon clearance of psoriatic plaques and nor-
malization of skin homeostasis, the therapeutic
objective shifts to the maintenance of a relap-
se-free state. Psoriatic inflammation tends to
recur in the previously affected skin locations,
which may be caused by the expression and
reactivation of inflammatory cytokines present
in the apparently normalized, plaque-free skin
after treatment [34, 35]. New data indicate that
combination treatment is able to induce T-reg
cells as well as counteract the activation and
differentiation of cytotoxic T-cells more effec-
tively than corticosteroids alone [27]. Further
clinical studies are required to explore the
possibility of combination treatment for the
long-term management of psoriasis (see Fig. 4e).
Fig. 3 Summary of the effects of corticosteroids and
vitamin D analogs on T-cell subsets involved in psoriasis
pathogenesis [33]. Th17-cells are more involved in
psoriasis pathogenesis than Th1 cells. The upward and
downward arrows indicate induction and downregulation
of T-cells, respectively, by calcipotriol and steroid. DC
dendritic cells, FOXP3 Forkhead box P3, IFN interferon,
IL interleukin, MHC major histocompatibility complex,
TCR T-cell receptor, Th T-helper cell, T-reg regulatory
T-cell Adapted from Bailey et al. [33]
Summary: Combination Therapy
has Complementary Effects
on the Underlying Pathophysiology
of Psoriasis, Resulting in Increased
Therapeutic Response
1. As well as their normalizing effect on
keratinocytes, vitamin D analogs, such as
calcipotriol, exert immunomodulatory
effects on Th1, Th2, Th17, and T-reg cells.
2. Corticosteroids, such as betamethasone
dipropionate, combined with vitamin D
analogs, additively inhibit Th1 and Th17
pro-inflammatory effects.
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Corticosteroid and Vitamin D Analog
Combination Therapy Attenuates Side
Effects Associated with their Individual
Monotherapies
Corticosteroid and vitamin D analog
monotherapy is associated with increased risks
of skin atrophy and perilesional skin irritation,
respectively [4, 16, 36]. As the frequency of
application of corticosteroids and vitamin D
analogs used in combination therapy is lower
than in monotherapy [4], the risk of adverse
events associated with monotherapy is reduced
[16, 37, 38].
Long-term continuous use of topical corti-
costeroid treatment alone can lead to skin
atrophy. As a result, the thickness of the skin is
reduced and transepidermal water loss increa-
ses, causing loss of skin barrier function [37, 39].
Recent studies in cultured skin cells have
demonstrated that the addition of calcipotriol
reduces the early signs of betamethasone and
clobetasol-induced skin atrophy by modulating
key ECM components [39]. The effects of corti-
costeroid, vitamin D analog, and combination
treatment during skin atrophy are summarized
in Table 1.
3. Calcipotriol induces an immunomodula-
tory Th2/T-reg cellular response, whereas
corticosteroids suppress this effect, and
combination treatment yields mild
induction.
4. The preclinical results support the supe-
rior antipsoriatic effect of corticosteroid
and vitamin D analog combination treat-
ment compared with monotherapies.
Fig. 4 Summary of the complementary and additive
actions of corticosteroid and vitamin D analog combina-
tion treatment on cellular targets in the pathophysiology of
psoriasis. a–d Therapeutic targets for inhibiting the
pro-inflammatory environment. e Possible key targets for
long-term maintenance therapy. Asterisk: Resting and naı¨ve
dendritic cells and T-cells; plus and minus signs: indicate
induction and inhibition, respectively. DC dendritic cell,
IL interleukin, Tc cytotoxic T-cell, Th T-helper cell, TNF
tumor necrosis factor, T-reg regulatory T-cell
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Calcipotriol as monotherapy (50 lg/g twice
daily doses) may cause perilesional skin irrita-
tion [16, 36]; however, the addition of a corti-
costeroid has shown a beneficial effect: a
52-week study demonstrated that daily treat-
ment with Cal/BD ointment (Cal 50 lg/g and
BD 0.5 mg/g) significantly reduced the overall
number of adverse events—particularly burn-
ing, itching, or erythema of the skin—compared
with vitamin D analog monotherapy (Cal oint-
ment, 50 lg/g) [40].
Authors’ clinical opinion The improved
safety profile of fixed-dose topical combina-
tion treatment, together with the once-daily
treatment use, offers improved convenience
and better acceptance compared with
monotherapies [42, 43]. These factors are
essential in the therapeutic armamentarium
for psoriasis and are likely to facilitate adher-
ence to treatment, which may subsequently
lead to faster and greater improvements in
patient QoL.
Table 1 Summary of the effects of corticosteroids and vitamin D analogs in skin atrophy [37, 39, 41]
Mechanism Effect of
corticosteroids
Effect of vitamin
D analogs
Overall clinical effect of combination treatment
Lipid synthesis  æ Prevents skin barrier and water loss impairment caused by
corticosteroidsAMPs, e.g., LL-37  æ
KC proliferation*  = Attenuates epidermal thinning by corticosteroid-induced
reduction of epidermal cells
Change in tissue
modeling and
structure:
–Hyaluronic acid
–Matrix
metalloproteinases
 æ Limits epidermal thinning from corticosteroid-induced
loss of cellular volume
Collagen synthesis and
turnover
 æ Reduces dermal thinning caused by corticosteroid induced
decrease in matrix network
Glycosamine synthesis  æ Increases water-binding capacity of the skin, decreasing
corticosteroid-induced dermal thinning
Elastic fiber synthesis  æ Attenuates reduced skin flexibility/elasticity observed in
topical steroidal monotherapy
Downward arrow indicates downregulation; upward arrow indicates upregulation; equal sign indicates no effect; AMPs
antimicrobial peptides; KC keratinocytes
* KC proliferation is psoriasis activity-dependent. The data presented here are based on non-inflamed skin
Summary: Combination Treatment
Minimizes Skin Atrophy and Decreases
Other Monotherapy-Related Risks
1. Long-term continuous use of corticos-
teroids leads to skin atrophy. Vitamin D
analogs can reduce corticosteroid-in-
duced skin atrophy by modulating key
ECM components.
2. Combination treatment reduces the fre-
quency of application of corticosteroid
and vitamin D analogs used to treat
psoriasis compared with monotherapy.
This leads to a significant reduction of
adverse events associated with monother-
apies of both active ingredients.
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CHALLENGES OF DRUG DELIVERY
IN TOPICAL FORMULATIONS
Poor penetration of active ingredients into the
skin can result in low, or lack of, clinical effi-
cacy; therefore, considerable research has been
undertaken to improve drug delivery in topical
formulations. The ability for an active ingredi-
ent to penetrate the skin depends primarily on
(1) the condition of the skin barrier, (2) the
physicochemical properties of the combined
drug and vehicle, and (3) the concentration of
active ingredients dissolved into the vehicle.
1. Condition of the skin barrier Skin permeability
depends on hydration levels on the outer
surface [44, 45]. Occlusion of the skin by
plastic wraps, impermeable dressings, or
vehicles containing fats or polymer oils—
such as oils, gels, and ointments—are well--
known methods to increase skin hydration
levels and thus influence the permeability of
active ingredients of topical treatments [44].
2. Physicochemical properties of combined drug
and vehicle Physicochemical properties, such
as the shape, lipophilicity, viscosity, occlu-
sive properties, charge, and size, of both
active ingredients, as well as excipients,
influence the partitioning of the active
ingredients between the vehicle and skin
and their subsequent ability to penetrate
the skin [11, 45].
3. Concentration of active ingredients dissolved
into the vehicle The rate of skin penetration is
proportional to the concentration of active
ingredient dissolved in the vehicle because
of the resulting increase in thermodynamic
activity [12, 46, 47]. This is a rate-limiting
step for most topical treatments, whose
active ingredients have limited solubilities
in their vehicles. One potential method to
enhance the rate of skin penetration is to
increase the concentration of active ingre-
dients dissolved in the applied product
beyond the normal solubility limit—i.e., to
create a supersaturated solution. A recent
study demonstrated that a supersaturated
environment was created and maintained
with Cal/BD when applied as an aerosol
foam; this state was created after rapid
evaporation of the propellants during appli-
cation [11]. A supersaturated solution is
only clinically relevant if it is stable, as
crystallization of ingredients will decrease
penetrative properties of the treatment [46].
Results from the same study showed that
the supersaturated solution of Cal/BD aero-
sol foam was maintained in the laboratory
setting, post-application, for clinically rele-
vant time periods (at least 26 h in the
laboratory setting) [11], which may explain
the observed increase in bioavailability of
Cal/BD aerosol foam versus Cal/BD oint-
ment [11].
CLINICAL BENEFITS
OF CORTICOSTEROID
AND VITAMIN D ANALOG
FIXED-DOSE COMBINATION
TREATMENT
Corticosteroids and vitamin D analogs are
directed at different targets in the pathogenesis
of psoriasis. Their complementary and additive
effects observed in preclinical data have been
translated into effective fixed-dose combination
therapies. The corticosteroid component largely
allows for fast and efficacious anti-inflamma-
tory effects, whereas the vitamin D analog
ensures durability of the treatment and possible
Summary: Challenges in Drug Delivery
1. Enhancing the penetration of active
ingredients into the skin is one of the
main challenges in topical drug delivery.
2. The success of drug delivery depends on
skin hydration levels, physicochemical
properties of the combined drug and
vehicle, and the concentration of active
ingredients dissolved into the vehicle.
3. A modified, stable supersaturated solu-
tion—such as the one observed with Cal/
BD aerosol foam—may contribute to the
superior efficacy observed when com-
pared with more traditional vehicles,
e.g., ointment and gel.
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maintenance of a relapse-free state. The current
clinical evidence for corticosteroid and vitamin
D analog combination treatment, and what this
means for the treating physician, are discussed
below.
Corticosteroid and Vitamin D Analog
Fixed-Dose Combination Treatment is
More Efficacious than Monotherapies
in Treating the Underlying Psoriasis
The superior efficacy of corticosteroid and vita-
min D analog combination treatment compared
with monotherapy is supported by randomized,
double-blind controlled clinical studies [48, 49].
A three-arm, multicenter study demonstrated
that fixed-dose combination Cal/BD aerosol
foam was significantly more efficacious in
improving the mean modified Psoriasis Area
and Severity Index score (mPASI; excluding the
head, which was not treated) than the individ-
ual active ingredients after 4 weeks (P\0.001
versus both Cal foam and BD foam) [48]. These
data were supported in a plaque test study
where the total clinical score, which measures
the changes in erythema, scaling, and plaque
thickness, was significantly improved with Cal/
BD foam compared with BD foam after 4 weeks
of treatment (P = 0.005) [49].
As well as providing efficient anti-inflam-
matory effects, the use of vitamin D analogs
may also lead to long-term management of
psoriasis by inducing immunomodulatory
responses. Combination therapy with cal-
cipotriol and betamethasone butyrate propi-
onate ointment was associated with a decrease
in T-cell production of the pro-inflammatory
cytokines IL-17 and IFN-c, which correlated
with a significant improvement in mean PASI
score in patients with moderate-to-severe pso-
riasis [50].
Authors’ clinical opinion Targeting specific
molecules involved in the pathophysiology of
psoriasis, as observed in fixed-dose combination
treatment, results in an early and rapid
response. This helps build patient confidence in
the treatment and positively impacts QoL and
adherence to therapy. These aspects could, in
turn, help in developing a mutually trusting
and successful patient-dermatologist partner-
ship. Additionally, patients can personally
adapt fixed-dose combination treatment during
long-term management. For example, in cases
of flares, patients can increase the frequency of
application and reduce it accordingly once the
flare has been controlled.
An Innovative Drug Delivery Formulation
Results in Improved Efficacy
A number of studies have demonstrated the
superior efficacy of Cal/BD aerosol foam for-
mulation compared with traditional formula-
tions, such as ointments, gels, and lotions
(Table 2) [49, 51–53]. For example, in two 4--
week Phase II studies, Cal/BD aerosol foam
demonstrated significant improvements in
mPASI (P = 0.005) [51] and plaque symptom
severity (P = 0.038) [49] compared with Cal/BD
ointment. In a Phase III study designed to
compare Cal/BD aerosol foam and Cal/BD gel
based on the recommended US/European
treatment periods (4 weeks for Cal/BD aerosol
foam, and 8 for Cal/BD gel), significantly more
patients treated with aerosol foam than gel had
clear/almost clear skin at weeks 4 and 8,
respectively (P\0.001; defined as C2 grade
improvement according to the Physician’s
Global Assessment of disease severity) [53].
Results from health-related QoL questionnaires,
such as Dermatology Life-Quality Index (DLQI),
were also significantly improved with Cal/BD
aerosol foam than with Cal/BD gel [52]. Nota-
bly, significantly more patients treated with
Cal/BD aerosol foam reported that psoriasis no
longer impacted their daily lives (i.e., achieved
DLQI scores of 0/1) at week 4 compared with
patients treated with Cal/BD gel (45.7% vs.
32.4%; P = 0.013) [52]. One aspect of psoriasis
that has a strong negative impact on patient
QoL is itch [54]. Improvements in DLQI scores
after 4 weeks of Cal/BD aerosol foam treatment
were significantly correlated with improve-
ments in itch VAS scores [55]. Cal/BD aerosol
foam also provided fast and significantly greater
itch relief than placebo (P = 0.013 at day 3) [56].
Furthermore, the superior efficacy of Cal/BD
aerosol foam is associated with a similar safety
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profile, as demonstrated in a pooled safety
analysis of three clinical studies comparing
fixed combination Cal/BD aerosol foam with
BD foam, Cal foam, Cal/BD ointment, and
vehicles (foam and ointment) [57].
Authors’ clinical opinion Cal/BD aerosol foam
treatment can significantly reduce the burden
of the disease, as demonstrated by the superior
efficacy and ability to provide significant and
measurable improvement in QoL compared
with conventional Cal/BD formulations, such as
gel and ointment. The rapid itch relief associ-
ated with Cal/BD aerosol foam is crucial for
treatment success as patients perceive itch to be
Table 2 Summary of studies comparing Cal/BD aerosol foam with Cal/BD gel or ointment
References Study
identifier
Design Duration
(weeks)
N Comparator(s) Outcomes
Queille-Roussel
[49]
NCT01347255 Phase IIa,
exploratory,
single-center,
intra-individual
comparison
4 24 Cal/BD foam vs.
Cal/BD ointment
vs. BD foam vs.
foam vehicle (all
n = 24)
TCS decrease: -6.00
vs. -5.25 (Cal/BD
ointment;
P = 0.038), vs.
-4.96 (BD foam;
P = 0.005)
Koo et al. [51] NCT01536886 Phase II,
randomized,
multicenter
4 376 Cal/BD foam
(n = 141) vs. Cal/
BD ointment
(n = 135) vs.
foam (n = 49)
and ointment
(n = 51) vehicle
Treatment success
rates: 54.6% vs.
43.0% (Cal/BD
ointment;
P = 0.025); mPASI
mean difference:
-0.6 vs. Cal/BD
ointment
(P = 0.005)
Paul et al. [52] NCT02132936 Phase III,
randomized,
parallel-group
(PSO-ABLE)
12 463 Cal/BD foam
(n = 185) vs. Cal/
BD gel (n = 188)
vs. foam (n = 47)
and gel (n = 43)
vehicle
Treatment success
rates: 38% vs. 22%
(Cal/BD gel;
P\0.001); mPASI
mean difference:
-0.6 vs. Cal/BD gel
(P = 0.028)
Paul et al. [53] NCT02132936 Phase III,
randomized,
parallel-group
(PSO-ABLE
secondary,
HRQoL
analysis)
12 463 Cal/BD foam
(n = 185) vs. Cal/
BD gel (n = 188)
DLQI scores of 0/1:
61% vs. 44% (Cal/
BD gel; P = 0.003);
EQ-5D utility index:
0.09 vs. 0.03 (Cal/
BD gel; P\0.001)
All studies were investigator-blinded
BD bethamethasone dipropionate 0.5 mg/g, Cal calcipotriol 50 lg/g, DLQI Dermatology Life Quality Index, EQ-5D
EuroQoL-5D-5L-PSO, HRQoL health-related quality of life, mPASI modified Psoriasis Area and Severity Index (excluding
the head, which was not measured), TCS total clinical score (sum of erythema, scaling and plaque thickness)
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one of the most bothersome symptoms of pso-
riasis. Due to its improved efficacy and positive
impact on QoL, with no additional concerns
about tolerability, Cal/BD aerosol foam is not
just an improvement on previous formulations,
but could also be considered a new stand-alone
treatment.
CONCLUSIONS
Fixed-dose combination of corticosteroids and
vitamin D analog has demonstrated superior
efficacy over monotherapies with topical ster-
oids in both preclinical and clinical studies, as
well as in daily practice. Updated knowledge on
the mechanism of action of the active ingredi-
ents demonstrates how combination treatment
successfully and significantly inhibits active
inflammation and supports the maintenance of
a relapse-free state. The rationale for fixed-dose
combination treatment is further supported by
the fact that adverse events associated with
corticosteroid and vitamin D analog
monotherapy, such as skin atrophy and perile-
sional skin irritation, respectively, can be effec-
tively minimized by combining the two active
ingredients. Improved delivery of the active
ingredients via innovative formulations, such as
an aerosol foam, has shown improved clinical
response and QoL, while providing patients
with more therapeutic options suited to their
lifestyle. Additional research is still required to
understand how long-term maintenance of a
disease-free state can be achieved in the clinical
setting. For this reason, a randomized clinical
trial with Cal/BD aerosol foam has recently been
initiated to examine the long-term manage-
ment of plaque psoriasis (PSO-LONG;
NCT02899962).
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